secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2026-08-06T12:03:18+00:00
Accession:  0001000694-26-000019
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax Q2 2026 revenue $57M, net loss $53M; raises full-year revenue framework to $235-275M
--------------------------------------------------------------------------------

- Total revenue $57M (down 76% YoY); net loss $53M vs net income $107M in Q2 2025.
- Raised full-year 2026 Adjusted Total Revenue framework to $235-275M (from $230-270M).
- Sanofi partnership: Phase 3 CIC trial start triggers $125M milestone; tech transfer completion mid-2027 triggers $75M milestone.
- Cash $724M as of June 30, 2026, down from $751M at Dec 31, 2025.
- Combined R&D and SG&A expense guidance improved to $370-410M (from $380-420M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000100069426000019/0001000694-26-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000100069426000019/nvax-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001000694-26-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer